Inovio Pharma (INO)

Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase…

Avoid Taking a Bet on the Deep Correction In Inovio Stock

By Chris Tyler, InvestorPlace Contributor Nov 2, 2020

Small-cap biotechs are inherently challenging. With a failed INO-4800 timeline, INO stock increasingly finds itself back in this group.

Avoid Inovio Pharmaceuticals Stock Until the FDA Greenlights Trials

By Ian Cooper, InvestorPlace Contributor Oct 30, 2020

While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.

Inovio Investors Need FDA to Write Positive Prescription for Stock Gains

By Todd Shriber, InvestorPlace Contributor Oct 29, 2020

The bad news is that the FDA recently halted the Inovio trial. Think about that for a moment. The world is in dire of need of a Covid-19 vaccine and the U.S. is engaged “Operation Warp Speed” to get a vaccine to market, but here's a regulator telling Inovio to pump the brakes.

The FDA’s Questions Aren’t a Deal Breaker for Inovio Stock

By Louis Navellier and the InvestorPlace Research Staff Oct 27, 2020

INO stock is down but not out as the development of a Covid-19 vaccine is bound to have some bumps in the road.

Could the FDA Be Ready to Crash Inovio’s Hopes and Dreams?

By Will Ashworth, InvestorPlace Contributor Oct 23, 2020

It’s been a month since the FDA put Inovio’s Covid-19 vaccine on partial clinical hold. No news is definitely not good news for INO stock.

Time Is Running Out on Inovio as Other Vaccine Candidates Advance

By Faizan Farooque, InvestorPlace Contributor Oct 22, 2020

The FDA's latest decision has dealt a killer blow to INO stock, which was already struggling to keep up with Big Pharma in the vaccine race.

Investors Should Buy the Phase II/III Dip in Inovio

By Muslim Farooque, InvestorPlace Contributor Oct 22, 2020

INO stock is in a rough spot of late, but it is poised to bounce back from these temporary setbacks with a strong product portfolio.

Why the FDA’s Inquiry of Inovio Is More Critical Than You Think

By Josh Enomoto, InvestorPlace Contributor Oct 19, 2020

INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here’s why you should be concerned.

Avoid Inovio Like the Plague After Its 64% Price Drop

By Joel Baglole, InvestorPlace Contributor Oct 13, 2020

INO stock has fallen more than 60% since June and further declines look imminent as the company struggles with its Covid-19 vaccine.

Inovio Stock Is a Great Long Setup for an Overreaction Trade

By David Moadel, InvestorPlace Contributor Oct 13, 2020

A freak-out ensued after the FDA placed a halt on Inovio's Covid-19 vaccine trials, but the price dip is a chance to buy INO stock cheaper.

Avoid Inovio Pharmaceuticals Like the Plague

By Lou Carlozo, InvestorPlace Contributor Oct 12, 2020

The pharma is pursuing a Covid-19 vaccine. But INO stock is risky as the company has failed to bring a product to market for 40 years.

Inovio Pharmaceuticals Does Not Need Any More Misfortune

By Chris Markoch, InvestorPlace Contributor Oct 7, 2020

INO stock is plummeting after the FDA put a hold on its INO-4800 vaccine candidate. But by the time Inovio resumes the trial, will a vaccine be needed?